Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Pakistan Emerging Markets

Pakistan Drug-Pricing Authority Lowers Prices Of 92 Life-Saving Drugs

This article was originally published in PharmAsia News

Executive Summary

Pakistan's newly constituted Drug Regulatory Agency of Pakistan moved to reduce the prices of 92 life-saving drugs as well as taking other actions to restrict the prices of pharmaceuticals on a regular basis.

Pakistan's newly constituted Drug Regulatory Agency of Pakistan moved to reduce the prices of 92 life-saving drugs as well as taking other actions to restrict the prices of pharmaceuticals on a regular basis. The panel's drug-pricing committee said it ordered the lower prices and took steps to make pricing rational and transparent on the part of drug makers and its own regulations. The DRAP also said its various units would meet regularly to dispose of a year's backlog of issues. (Click here for more)

"Committee Formed To Check Medicine Prices Regularly" - Pakistan News Service (7/4/2012)

Table

View full table

Topics

Tags:
BioPharmaceutical Pakistan Emerging Markets
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC081806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By